lorviqua
pfizer europe ma eeig - lorlatinib - karcinoma, nesmulkiųjų ląstelių skausmas - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
maxitrol
limedika, uab - deksametazonas/neomicino sulfatas/polimiksino b sulfatas - akių lašai (suspensija) - 1 mg/3500 tv/6000 tv/ml - dexamethasone and antiinfectives
metilprednisolona normon
lex ano, uab - metilprednizolonas - milteliai ir tirpiklis injekciniam tirpalui - 40 mg - methylprednisolone
tobrex
lex ano, uab - tobramicinas - akių tepalas - 3 mg/g - tobramycin
maxidex
lex ano, uab - deksametazonas - akių lašai (suspensija) - 1 mg/ml - dexamethasone
ciloxan
lex ano, uab - ciprofloksacinas - akių lašai (tirpalas) - 3 mg/ml - ciprofloxacin
travoprost sandoz
lex ano, uab - travoprostas - akių lašai (tirpalas) - 40 µg/ml - travoprost
kventiax
actiofarma, uab - kvetiapinas - plėvele dengtos tabletės - 25 mg - quetiapine
tobrex
lex ano, uab - tobramicinas - akių lašai (tirpalas) - 3 mg/ml - tobramycin
metilprednisolona normon
adeofarma, uab - metilprednizolonas - milteliai ir tirpiklis injekciniam tirpalui - 40 mg - methylprednisolone